Combined RT-CHT in a concomitant setting is the standard of cancer for anal cancer patients [
11]. In Europe, split-course high-dose RT was mostly chosen as a treatment option following established seminal works [
20]. A treatment gap was planned between the first large-field phase and the second boost phase on the macroscopic disease. The gap was intended to allow for the resolution of acute skin and mucosa toxicity and for tumor response assessment to better tailor the subsequent overdosage on the residual disease [
7]. This approach was set by 2 randomized phase III trials namely the ACT I and EORTC 22861 trials, which demonstrated the benefit of adding CHT over RT alone, in terms of local control, sphincter preservation rate and overall survival [
21,
22]. In these trials, RT was given employing 2 treatment sequences delivered sequentially. In the EORTC 22861 trial, 45 Gy over 5 weeks were given using conventional fractionation to the whole pelvis followed, after a 6-week interval, by a boost dose modulated according to treatment response (20 Gy to partial and 15 Gy to complete responders) and delivered thorough photons, electrons or
192Ir implants [
21]. Concomitant CHT (continuously infused 5-FU and bolus MMC) was given only during the first treatment sequence [
21]. Similarly, in the ACT I trial, the first phase was made up of 45 Gy in 20 or 25 fraction over 4 to 5 weeks, while the boost (given to complete or > 50% partial responders) employed 15 Gy in 6 fractions with photons or electrons or 25 Gy given at 10 Gy per day given with iridium implants [
22]. Mitomycin C was given at the beginning of the first phase and 5-FU at the beginning and end of it. In the US, clinical researches mostly employed a moderate dose and continuously delivered RT course associated to concurrent chemotherapy as in the RTOG 8704-ECOG 1289 trial, in which patients were treated up to 45–50.4 Gy, with field reduction at 30.6–36 Gy, with concurrent 5-FU ± MMC for 2 cycles [
23]. Based on the observation that accelerated tumor cell repopulation occurs during RT and may have detrimental effects on clinical outcomes, clinical research started to shorten treatment regimens to decrease overall treatment time [
24]. For example the EORTC 22953 phase II trial, investigated the feasibility and toxicity profile of a reduction in the gap period between the whole pelvis phase and the boost to 2 weeks, together with the intensification of the CHT regimen [
25]. The compliance to therapy in terms of delivered dose and treatment duration was 93%, with a complete response rate of 90.7% [
25]. More recently, SeqB approaches were delivered with no pre-planned interruptions as in the ACT II trial and represent, nowadays, the standard treatment strategy [
2]. Neverthelss, compared to the SeqB approach, SIB potentially allows for a further reduction in the OTT, because treatment fractions are continuously delivered and different daily doses to target volumes are given in the same number of fractions [
1,
10]. In the attempt to investigate whether SIB may provide a therapeutic gain, we analyzed 2 cohorts of anal cancer patients treated with SIB and SeqB approaches. To the best of our knowledge, this is the first study comparing these 2 treatment strategies in terms of CFS in anal cancer patients. Median follow up was similar for the 2 groups (34 vs 31 months for SIB and SeqB). Focusing on patients characteristics, the 2 cohorts were different since the SeqB group had a significant higher proportion of patients with tumor of the anal margin (22.3% vs 16.1%;
p < 0.0001), with positive nodes (48.5% vs 34.5%;
p = 0.0015), inguinal groin localization (35.9% vs 20.7%;
p = 0.0187), and G3 differentiation (24.1% vs 16.5%;
p = 0.0003). Borderline significant difference was found for advanced stage (IIIA-IIIB: 54.4% vs 38.0%;
p = 0.0730). Conversely, patients in the SIB group had a longer time between biopsy and RT start (patient with time ≥ 60 days: 66.7% vs 49.5%;
p = 0.0172). Median OTTs were 43 and 60 in the SIB and SeqB groups, respectively, due to the different approaches in delivering radiation. Local relapse rate was slightly higher for patients submitted to sequential boost (SeqB: 20.4% vs SIB: 18.4%), as were regional failures (SeqB: 7.8% vs SIB: 6.9%). A higher percentage of distant metastasis was observed in the SIB group (14.9%) compared to the SeqB group (5.8%), even if baseline patients characteristics were more favorable for these patients. A slightly, but non significant, higher colostomy rate was seen in the SeqB group (16.5% vs 13.8%). Noteworthy, in this group, one surgical procedure was performed because of functional issues in this cohort.
After adjusting for known prognostic factors, the effect of undergoing different treatments highlighted an AdjHR with respect to 2-year CFS for the first 24 months of 0.95 (95%CI:0.49–1.84,
p = 0.877), with an HR supposedly favoring the SIB approach, even if with a confidence interval containing the value 1 and thus not considerable as statistically significant (Fig.
1). We focused on the first 2 years because, for 17 out of 103 patients in the SeqB group, we could not retrieve an updated follow up (last observation time between 1 and 4 years from analysis), which could potentially affect the CFS rates as death from any cause is considered as an event. Interestingly, the cumulative incidence of colostomies at 1 and 2 years was higher in SeqB group (13.9%;95%CI:7.8–21.8 and 18.1%;95%CI: 10.8–27.0, respectively) compared to those of the SIB group (8.2%;95%CI:3.6–15.2 and 15.0%;95%CI: 8.1–23.9, respectively). We can hypothesize that it may suggest an explanation for the observed HR with respect to 2-year CFS when considering the SIB group. This observation may potentially be ascribed to the reduction in OTT given by the SIB strategy, but others clinical factors related to both patient and tumor that were not taken into account in the present analysis might have a consistent role. Given the retrospective nature of the present study and the unbalancement in terms of clinical characteristics between the 2 groups, we could not assess the superiority of one approach over the other nor the equivalence between them. Nevertheless, the clinical results reported within the SIB group are reassuring and strongly suggest the equipoise between the two strategies. Confirmatory prospective randomized trials would be need to prove this hypothesis. It is also interesting to observe that, albeit having a higher proportion of patients with high risk features in the SeqB group, no significant outcome differences were observed. A potential role of stage migration due to the use of inguinal SLNB in the SIB group can be pointed out to partially explain this finding. Several series have shown the detrimental effect of a longer OTT in anal cancer patients submitted to concurrent RT-CHT. Weber et al. have shown the a gap longer that 37.5 days had a significant effect on clinical outcomes in patient treated with split- course radiation [
7]. In their series patients with a longer gap had a 75% loco-regional control rate compared to 92.3% for patients with a shorter gap [
7]. Graf et al. found that OTT > 41 days significantly affected 5-year local control in anal cancer patients treated with RT-CT, as the rate was 58% for patients having OTT > 41 days and 79% for those with a OTT < 41 days (
p = 0.04) [
14]. This correlation was found regardless of the treatment approach used, either split-course or continuously delivered radiation. Pooled data analysis of patients enrolled in the RTOG 8704 and RTOG 9811 trials have shown a correlation between OTT and local failure, loco-regional failure, colostomy failure and time to failure, but not with CFS or OS [
26]. In the RTOG 92–08 trial, dose escalation up to 59.9 Gy concurrent to 5-FU and MMC was investigated with a mandatory 2-week gap after 36 Gy [
27]. Clinical outcomes were poor even with a higher dose delivered, suggesting a detrimental effect even of a short gap. Comparison between patients with similar characteristics having a 2-week gap (RTOG 9208) and those without (RTOG 8704) highlighted poorer results for patients with a longer gap [
25]. The aforementioned clinical data are explained from a radiobiological point of view by accelerated repopulation that occurs after irradiation and may lead to a loss in tumor control of 1–2% and of 0.4–0.6 Gy for each day of OTT extension [
28,
29]. Split-course studies demonstrated that a gap longer than 15 days may consistently affect clinical outcomes [
28,
29]. Our study has some limitations including its retrospective nature, the missing of updated follow up for some patients in the SeqB cohort, the lack of the chance to adjust results for all tumor- and patient-related factors potentially affecting clinical outcomes and the maximum reliability of the analysis for the first 24 months of follow up only. Moreover the sample size determination might not be adequate enough to detect a small difference in clinical outcomes. Hence, our data cannot be considered conclusive. Another important limit is the lack of robust data on the toxicity profile that did not allow us to compare the 2 approaches with respect to this endpoint. The only toxicity endpoint analysed in the present study was hematologic toxicity which did not show any difference in the 2 groups with respect to ≥ G3 events. Toxicity data from the RTOG 0529 trial showed a reduction of skin, gastro-intestinal and hematologic toxicity for patients treated with dose-painted IMRT compared to standard treatment. The same treatment schedule was adopted in the SIB group of the present study.
Nevertheless, the comparison between SeqB and SIB approaches seems to suggest that SIB is non-inferior to SeqB in terms of probability of being alive without a colostomy in anal cancer patients, and it could be a valid approach in this clinical setting. A potential advantage in terms of CFS can be hypothesized for SIB due to the shortening in OTT, but this possible finding need to be confirmed with more robust and prospective data.